# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate o...
Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and lowers the price target f...
Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Outperform rating a...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...
Wells Fargo analyst Jim Birchenough maintains Regulus Therapeutics (NASDAQ:RGLS) with a Equal-Weight and raises the price ta...
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up ...
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.